Intermittent administration of human parathyroid hormone enhances bone formation and union at the site of cancellous bone osteotomy in normal and ovariectomized rats

Bone ◽  
2008 ◽  
Vol 42 (1) ◽  
pp. 90-97 ◽  
Author(s):  
Koji Nozaka ◽  
Naohisa Miyakoshi ◽  
Yuji Kasukawa ◽  
Shigeto Maekawa ◽  
Hideaki Noguchi ◽  
...  
1999 ◽  
pp. 70-74 ◽  
Author(s):  
P Morley ◽  
JF Whitfield ◽  
GE Willick ◽  
V Ross ◽  
S MacLean ◽  
...  

OBJECTIVE: Daily injections of human parathyroid hormone (hPTH) increase bone volume in various animal species and in osteoporotic women. For hPTH to be widely accepted as an anabolic therapy for treating postmenopausal osteoporosis alternative delivery options need to be explored to replace the need for daily patient subcutaneous self-injection. Among these are inhalation, oral delivery and the use of programmable implanted minipumps to deliver the peptide. While infusion of high doses of PTH causes bone loss and hypercalcemia, no studies have assessed the effects of prolonged infusion of low doses of PTH on bone growth. DESIGN AND METHODS: [Leu(27)]-cyclo(Glu(22)-Lys(26))-hPTH-(1--31)NH(2) was delivered by Alzet minipumps to ovariectomized rats for 6 weeks after which histomorphometric indices (cancellous bone volume, trabecular thickness, mean trabecular number) of bone formation were measured in distal femurs. RESULTS: Infusing low doses (0.05 and 0.1 nmole/100g body weight/day) of the hPTH analog, [Leu(27)]-cyclo(Glu(22)-Lys(26))-hPTH-(1--31)NH(2), for 6 weeks does not prevent the ovariectomy-induced loss of rat femoral cancellous bone volume, trabecular thickness or trabecular number. CONCLUSION: These results support the absolute requirement of daily injections for the osteogenic action of hPTH on bone.


2000 ◽  
Vol 18 (1) ◽  
pp. 9-17 ◽  
Author(s):  
Masamitsu Nakajima ◽  
Sadakazu Ejiri ◽  
Mikako Tanaka ◽  
Ei-ichi Toyooka ◽  
Shoji Kohno ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document